Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Boehringer Ingelheim Clear all
Terminated Phase 2 Interventional Results available

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

NCT00748709
View directory record Official record
Conditions
Neoplasms
Interventions
BIBW 2992 (Afatinib)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Jul 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

NCT02115048
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Letrozole, Afatinib
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

Tiotropium (Spiriva) Rehabilitation Study

NCT00274521
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Deer Park, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia

NCT00673452
View directory record Official record
Conditions
Fibromyalgia
Interventions
duloxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2010 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Not applicable Interventional

Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease

NCT05781334
View directory record Official record
Conditions
Heart Failure, Type 2 Diabetes, Chronic Kidney Diseases
Interventions
Virtual Consult Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Jul 23, 2026, 8:14 PM EDT
Recruiting Phase 3 Interventional

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

NCT07107945
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Results available

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

NCT01976507
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
dabigatran etexilate mesylate
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Jul 23, 2026, 8:14 PM EDT
Completed No phase listed Observational Results available

Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT05870956
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
66 Years and older
Enrollment
1,798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Milton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 23, 2026, 8:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

NCT04822701
View directory record Official record
Conditions
COVID-19
Interventions
BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

NCT00826267
View directory record Official record
Conditions
Breast Neoplasms
Interventions
lapatinib, BIBW 2992, trastuzumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

NCT02832037
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
21
States / cities
Garden Grove, California • Lemon Grove, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

NCT01830127
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, BI 207127 high dose, Faldaprevir, BI 207127 low dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
La Mesa, California • San Diego, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Jul 23, 2026, 8:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

NCT01397201
View directory record Official record
Conditions
Asthma
Interventions
Placebo, BI 54903, Fluticasone propionate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

NCT02979977
View directory record Official record
Conditions
Squamous Cell Cancers of the Head and Neck
Interventions
cetuximab, afatinib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Results available

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

NCT04602221
View directory record Official record
Conditions
Healthy
Interventions
Lamotrigine, BI 409306, Placebo, BI 425809
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Results available

A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

NCT04137289
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Cholangiocarcinoma, Pancreatic Neoplasms
Interventions
BI 905711
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

NCT04846868
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
18
States / cities
Garden Grove, California • La Habra, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

NCT01019694
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
55
States / cities
Jasper, Alabama • Mobile, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Jul 23, 2026, 8:14 PM EDT
Recruiting Phase 1 Interventional

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

NCT05471856
View directory record Official record
Conditions
Solid Tumors
Interventions
BI 1703880, Ezabenlimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

NCT01370005
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Placebo, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
35
States / cities
Huntsville, Alabama • Phoenix, Arizona • Lincoln, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Jul 23, 2026, 8:14 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)

NCT02171156
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Winter Park, Florida • Skokie, Illinois • Muncie, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2017 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

NCT00002166
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ridgefield, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

NCT01669798
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
BIBF 1120
Drug
Lead sponsor
AA Secord
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Durham, North Carolina • Charlottesville, Virginia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Jul 23, 2026, 8:14 PM EDT